๋ฉด์—ญ์š”๋ฒ•์˜ ์ข…๋ฅ˜

 

1. NK์„ธํฌ ์š”๋ฒ•(Natural Killer Therapy)

๋ฆผํ”„๊ตฌ ์ค‘ NK์„ธํฌ(์ž์—ฐ์‚ดํ•ด์„ธํฌ)๋Š” ์ด์ƒ ํ‘œ์ ์— ๋Œ€ํ•œ ์ง€์‹œ๋ฅผ ๋ฐ›์ง€ ์•Š์•„๋„ ์Šค์Šค๋กœ ์•”์„ธํฌ ์ œ๊ฑฐ๋Šฅ๋ ฅ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค. ํ•œ๊ฐœ์˜ ์„ธํฌ ๊ณต๊ฒฉํ•˜๋ฉด ํœด์ง€ํ•˜๋Š” ํŠน์„ฑ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค.

2.ย ์ˆ˜์ง€์ƒ์„ธํฌ ์š”๋ฒ•(Dendritic Cells-based Therapy)

๋ง์ดˆ ํ˜ˆ์•ก ์ค‘์˜ ๋‹จํ•ต๊ตฌ๋กœ๋ถ€ํ„ฐ ๋ถ„ํ™”์‹œํ‚จ ์ˆ˜์ง€์ƒ ์„ธํฌ์—, ๊ทธ ํ‘œ์ ์˜ ์ •๋ณด๋ฅผ T์„ธํฌ์— ์ œ์‹œํ•˜๋Š” ๋Šฅ๋ ฅ์„ ์ฃผ์–ด ์ฒด๋‚ด์— ๋˜๋Œ๋ฆฌ๋Š” ์น˜๋ฃŒ๋ฒ•์ด๋‹ค. ํˆฌ์—ฌ๋œ ์ˆ˜์ง€์ƒ ์„ธํฌ๋Š” ํ™˜์ž์˜ ์ฒด๋‚ด์—์„œ T์„ธํฌ์— ํ‘œ์ ์˜ ์ •๋ณด๋ฅผ ์ „ํ•ด ํŠน์ •์˜ ์•”์„ธํฌ๋ฅผ ๊ณต๊ฒฉํ•˜๋Š” CTL์ด ํ™œ์„ฑํ™” ๋˜๋„๋ก ํ•˜๋Š” ๋ฐฉ๋ฒ•์ด๋‹ค.

3. ฮฑฮฒ-T์„ธํฌ ์š”๋ฒ•(ฮฑฮฒ T-lymphocyte Therapy)

๋ง์ดˆํ˜ˆ์•ก ์ค‘์— ํฌํ•จ๋˜๋Š” ฮฑฮฒ ํ˜• T์„ธํฌ, ฮณฮด ํ˜• T์„ธํฌ, NK์„ธํฌ, ๋‹จํ•ต๊ตฌ(MNC) ๋“ฑ์˜ ์„ธํฌ ์ „๋ฐ˜์„ IL-2์— ์˜ํ•ด ํ™œ์„ฑํ™” ๋ฐ ์ฆ์‹ ์‹œ์ผœ ํ™˜์ž ์ž์‹ ์˜ ์ฒด๋‚ด์— ๋˜๋Œ๋ฆฌ๋Š” ์น˜๋ฃŒ๋ฒ•์ด๋‹ค. ํŠน์ง•์€ ํ™œ์„ฑํ™” ๋œ ฮฑฮฒ-T์„ธํฌ๊ฐ€ ์ „์ฒด์˜ ์•ฝ 90% ๋ฅผ ์ฐจ์ง€ํ•˜๋Š” ๋ฐฉ๋ฒ•์ด๋‹ค.

4. ฮณฮด-T์„ธํฌ ์š”๋ฒ•(ฮณฮด T-lymphocyte Therapy)

๋ง์ดˆํ˜ˆ์•ก ์ค‘์— ํฌํ•จ๋˜๋Š” ฮณฮดํ˜• T์„ธํฌ๋ฅผ, Zoledronic acid๊ณผ IL-2 ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์„ ํƒ์ ์œผ๋กœ ํ™œ์„ฑํ™”, ์ฆ์‹ ์‹œ์ผœ ํ™˜์ž ์ž์‹ ์˜ ์ฒด๋‚ด์— ๋˜๋Œ๋ฆฌ๋Š” ์น˜๋ฃŒ๋ฒ•์ด๋‹ค.

5. CTL ์„ธํฌ ์š”๋ฒ•(Cytotoxic T Lymphocyte-based Therapy)

ํ‘œ์ ํ™”๋œ ์„ธํฌ๋งŒ ์„ ๋ณ„ํ•ด์„œ ํ•œ๋ฒˆ์— ํ•˜๋‚˜์”ฉ ์ฐจ๋ก€๋กœ ๊ณต๊ฒฉํ•œ๋‹ค. ํ‰์ˆ˜ ๋˜๋Š” ๋ณต์ˆ˜ ๋“ฑ์—์„œ ์–ป์„ ์ˆ˜ ์žˆ๋Š”, T์„ธํฌ๋ฅผ ์ž๊ทนํ•˜๋Š” ํŠน์ • ์•”์„ธํฌ๋ฅผ ๊ณต๊ฒฉํ•˜๋Š” ์„ธํฌ ์ƒํ•ด์„ฑ T์„ธํฌ(Cytotoxic T Lymphocyte)๋ฅผ ์–ป์–ด ํ–‰ํ•˜๋Š” ์น˜๋ฃŒ๋ฒ•์ด๋‹ค.

 

์ตœ๊ทผ ํŠธ๋ Œ๋“œ(Recently Trends)

์ตœ๊ทผ ์•”์น˜๋ฃŒ์—๋Š” NK์„ธํฌ์š”๋ฒ•(ANK์„ธํฌ์š”๋ฒ•์ด๋ผ๊ณ ๋„ ํ•จ),ย ฮฑฮฒ-T์„ธํฌ ์š”๋ฒ•์ด ๋งŽ์ด ์ด์šฉ๋˜๊ณ , ์ˆ˜์ง€์ƒ์„ธํฌ์š”๋ฒ•์˜ ๊ฒฝ์šฐ ์ž„์ƒ์—ฐ๊ตฌ ๋ฐ ํ™œ์šฉ์ด ์ง„ํ–‰๋˜๊ณ  ์žˆ๋‹ค.

TAG : ๋ฉด์—ญ์š”๋ฒ•, ๋ฉด์—ญ์„ธํฌ์น˜๋ฃŒ, ์•”์น˜๋ฃŒ, ๋ฉด์—ญ์„ธํฌ, ๋ฉด์—ญ๋ ฅ

Leave a reply

You must be logged in to post a comment.